Genmab As Stock Analysis

Genmab Pink Sheet Analysis Notes

About 50.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 1.2. Genmab AS recorded earning per share (EPS) of 12.0. The entity had not issued any dividends in recent years. Genmab AS develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. Genmab AS was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab AS is traded on OTC Exchange in the United States.The quote for Genmab AS is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To learn more about Genmab AS call Jan Winkel at 45 70 20 27 28 or check out https://www.genmab.com.

Genmab AS Investment Alerts

Genmab Market Capitalization

The company currently falls under 'Large-Cap' category with a current market capitalization of 26.78 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Genmab AS's market, we take the total number of its shares issued and multiply it by Genmab AS's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Genmab Profitablity

The company has Profit Margin (PM) of 0.47 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.38 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.38.

Technical Drivers

As of the 30th of November, Genmab AS retains the Standard Deviation of 2.89, risk adjusted performance of (0.08), and Market Risk Adjusted Performance of (1.29). Genmab AS technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Genmab AS variance and value at risk to decide if Genmab AS is priced fairly, providing market reflects its last-minute price of 212.5 per share. Given that Genmab AS has information ratio of (0.16), we strongly advise you to confirm Genmab AS's regular market performance to make sure the company can sustain itself at a future point.

Genmab AS Price Movement Analysis

Genmab AS Predictive Daily Indicators

Genmab AS Forecast Models

Genmab AS's time-series forecasting models are one of many Genmab AS's pink sheet analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Genmab AS's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Genmab AS prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Genmab shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as Genmab AS. By using and applying Genmab Pink Sheet analysis, traders can create a robust methodology for identifying Genmab entry and exit points for their positions.

When running Genmab AS's price analysis, check to measure Genmab AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab AS is operating at the current time. Most of Genmab AS's value examination focuses on studying past and present price action to predict the probability of Genmab AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab AS's price. Additionally, you may evaluate how the addition of Genmab AS to your portfolios can decrease your overall portfolio volatility.